HIV Infections Clinical Trial
— VIRAGE+Official title:
Feasibility and Effectiveness of a Pilot Program of Physical Activity to Improve HIV Related Functional Limitations and Disability in Adults Aged 40 and Older From Côte d'Ivoire: Baseline Evaluation
The goal of this interventional study is to document the importance of HIV-related disabilities, notably the frequency / nature of functional limitations, neurocognitive impairments, and restrictions of social participation in adults living with HIV aged 40 and older. Participants will undergo a comprehensive set of cognitive and functional assessments, and approximately twenty particpants will be asked to participate in an anthropological survey conducted through structured interviews. Researchers will a group of people living with HIV and o reference group without HIV infection.
| Status | Recruiting |
| Enrollment | 450 |
| Est. completion date | April 2024 |
| Est. primary completion date | April 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 40 Years and older |
| Eligibility | Inclusion Criteria: Participants living with HIV: - Age =40 years - Documented HIV-infection - Combined ART for =12 months - Written consent to participate to the study Controls: - Age =40 years - Negative HIV test within the last 12 months; - Living in Abobo area - Written consent to participate to the study Exclusion Criteria: Participants living with HIV: - HIV infection with HIV-2 type only - Any clinical symptoms suggesting an acute infection - Any life-threatening pathology in the short term or any pathology not allowing participation in the study Controls: - Any clinical symptoms suggesting an acute infection - Any life-threatening pathology in the short term or any pathology not allowing participation in the study |
| Country | Name | City | State |
|---|---|---|---|
| Côte D'Ivoire | Centre Médical Spécialisé El Rapha | Abidjan | |
| Côte D'Ivoire | Formation semi urbaine (FSU) d'Abobo Avocatier | Abidjan |
| Lead Sponsor | Collaborator |
|---|---|
| ANRS, Emerging Infectious Diseases | Centre Population et Développement (CEPED/IRD), Programme PAC-CI |
Côte D'Ivoire,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Performance at the 6' step-up test | Number of ascent-descent cycles counted over 6 minutes | Day 0 | |
| Primary | Performance at the 6' walking test | Measures distance covered during a 6-minute period of rapid walking on a flat and hard surface | Day 0 | |
| Primary | Performances at the 5 stand-up and sit test | Time required to perform 5 quick lifts from a seated position | Day 0 | |
| Primary | Performances at the Y balance Test | Sum of distances reached in each direction (the best is chosen for each direction) divided by 3 x length of lower limb (standardization) and multiplied by 100 | Day 0 | |
| Primary | Grip strenght | Force in kg measured with a dynamometer, twice per limb | Day 0 | |
| Primary | Short Physical Performance Battery (SPPB) score | Score between 0 and 12, with 0 indicating the worst performance and 12 the highest degree of functionality | Day 0 | |
| Primary | Scores of the Neuroscreen app tests | Score calculated by the application: that higher scores indicated better performance. | Day 0 | |
| Primary | WHO Disability Assessment Schedule - 2.0 (WHODAS) score | The higher the calculated score, the more significant the encountered difficulties | Day 0 | |
| Primary | HIV Disability Questionnaire - short form (HDQ-SF) score | The higher the calculated score, the more significant the encountered difficulties | Day 0 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |